WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy. The multicenter, randomized, double-blind, placebo-controlled trial is designed to assess the safety and potential efficacy of ALKS 5461 in subjects with TRD. Alkermes expects to provide topline results from this study in the second half of calendar 2011.
